Tenax Therapeutics Inc. (TENX) has garnered attention due to recent corporate and clinical developments that underscore advancements in its late-stage pipeline.
The company is advancing levosimendan, a first-in-class K-ATP channel activator and calcium sensitizer, for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This condition remains a significant unmet medical need, with no approved therapies currently available.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com